Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, November 22, 2023. Redwood Pharma AB (publ) announces today that the company will participate in Nordic Life Science Days, the Nordics' largest investor and partnering meeting, at the end of November.
Redwood Pharma's CEO Martin Vidaeus will participate in the Nordic Life Science Days, NLS Days, organized at the Bella Center in Copenhagen, Denmark, between November 29-30. NLS Days is the Nordic region's leading partner event that brings together investors and companies in the life science industry from several different countries.
"Our focus is now on spreading knowledge about our innovative dry eye treatments and our drug delivery technology IntelliGel. We noted a strong interest in our programs during the BIO Europe partnering conference in Munich earlier in November and look forward to continuing dialogue with potential partners," says Redwood Pharma's CEO, Martin Vidaeus.
RP501 is being developed to be an effective and user-friendly treatment for dry eye, a disease that affects more than 300 million people around the world. RP501 is based on IntelliGel - a patented and unique formulation that has the consistency of a drop of water when instilled into the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long time.